discontinuation of imatinib

OTHER2 trials

Sponsors

Japan Adult Leukemia Study Group, Oslo University Hospital

Conditions

Chronic Myeloid Leukemia Chronic phaseGastrointestinal Stromal Tumor

Phase 2

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group study

Active, not recruitingJPRN-UMIN000011971

Japan Adult Leukemia Study GroupChronic Myeloid Leukemia Chronic phase

Start: 2013-11-30Target: 62Updated: 2026-06-29

Unknown Phase

SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST

SuspendedNCT02924714

Oslo University HospitalGastrointestinal Stromal Tumor

Start: 2017-01-31End: 2022-11-30Target: 31Updated: 2022-02-18

Related Papers

Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor who are in complete radiological remission: A prospective multicenter phase II study.

Journal of Clinical Oncology2022-06-011 citations

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

2017-09-1972 citations